In full caption, these changes, although modest in magnitude, would point to an elevated 2-AG/AEA tone in metastatic melanoma owing to an increased 2-AG production (upregulation of DAGLα) and a reduced 2-AG/AEA bioconversion (downregulation of ABHD6/12 and FAAH, respectively), in concert with an elevated availability of the two bona fide 2-AG/AEA molecular targets, i.e., CB1R and CB2R. The gene discussed is DAGLA; the disease is metastatic melanoma.